Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims. Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. A site-change that invalidates stability claims is noise around an already-controlled CMC and Development Pathways process in a 505(b)(2) program relying on literature plus a bridging study, given pediatric investigation plan vs. disease epidemiology. 2. A site-change that invalidates stability claims is the event in pediatric investigation plan vs. disease epidemiology that forces Proceed under protocol for labeling negotiator under Pharma & Life Sciences. 3. Pediatric investigation plan vs. disease epidemiology shows a one-file miss after a site-change that invalidates stability claims, not a CMC and Development Pathways program failure. 4. Pediatric investigation plan vs. disease epidemiology cannot decide to drop a secondary yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read pediatric investigation plan vs. disease epidemiology against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims). If pediatric investigation plan vs. disease epidemiology cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, labeling negotiator must state the unresolved clinical or safety evidence requirement explicitly.